Secondly, the complete rejection of re-challenged tumor cells by the SART3/CD40L+GM-CSF vaccine, even in 40% of recipient mice, indicates the possibility of development of SART3-specific memory CD4+ T cells. Here, CD40LG is linked to neoplasm.